A new hormonal therapy designed to provide uterine fibroids called relugolix has finished a Phase 3 study in Japan, and the results are positive.
That’s acquire news for a SoftBank-backed company formed in Basel, Switzerland called Roivant Sciences that’s alone traffic with much lousier news.
But let’s back up a bit first.
The Phase 3 hearing was one of several Phase 3 trials of relugolix that are ongoing, including in the U.S. and Europe, where the drug is also being tested as a means to provide endometriosis-associated pain and to help men with modernized prostate cancer by suppressing their testosterone levels. The outcome out of Japan isn’t adequate to win it FDA approval, but Myovant, the biopharmaceutical company behind it, is approaching to use the outcome from Japan to support its capitulation here in the U.S.
Why does it matter? Well, for one thing, a win would be suggestive for Myovant, which staged the biggest biotech IPO of last year, shortly after recruiting Lynn Seely as its CEO. (Seely was before the arch medical officer of Medivation, which sole to Pfizer last year for $14 billion). In other words, expectations are high.
Myovant is also a auxiliary of Roivant, a immature holding company whose 32-year-old founder, Vivek Ramaswamy, believes will become a hulk holding company for dozens of eccentric biopharmaceutical companies.
Ramaswamy sole SoftBank on that prophesy over the summer, in fact, with SoftBank heading a $1.1 billion investment in the company (and getting a high bonus on its secretly held shares in the process, we’re told).
Then, disaster. More specifically, early last week, Axovant — another of Roivant’s holding companies that was taken open and itself wound up apropos the biggest biotech IPO of 2015 — perceived news that its much-hyped, initial Alzheimer’s drug, interpirdine, doesn’t work. (We wrote about that here.)
It was a outrageous blow to the company, whose shares plummeted 75 percent that day and have remained flat. It was also a black symbol for Roivant, which has told a convincing story until now about using information some-more effectively than big pharma companies that have exponentially some-more employees and resources.
Now, to recover his place as a wunderkind of the biotech world, Ramaswamy — a Harvard-educated biology major with a law grade from Yale — needs some certain momentum.
Relugolix is a smaller play for Roivant, but it’s not insignificant. According to one study, 70 percent of white women, and between 80 and 90 percent of black women, will rise fibroids by age 50, and 90 percent of women who are diagnosed with them find medical or surgical diagnosis of their fibroids within a year. (Many others don’t comprehend they have them.)
The reduction invasive track is, of course, medicine. In fact, reloguolix is anticipating to squeeze marketplace share of a hormone therapy already in the market: Leuprorelin, a product that first perceived FDA capitulation in 1985 and is now used in the diagnosis of hormone-responsive cancers like prostate cancer and breast cancer, as good as to treat estrogen-dependent conditions, including uterine fibroids and endometriosis. (It’s marketed under opposite brands by opposite companies. The German multinational organisation Bayer sells it as Viadur; the U.S. company Abbott Laboratories markets it as Lupor.)
There is still work to do; the other Phase 3 studies for relugolix were kicked off sincerely recently, definition it could be until closer to 2019 before the drug receives capitulation — if it’s means to win capitulation at all. In the meantime, another biopharma giant, AbbVie, is building a competing drug called elagolix, so the race is on.
In the meantime, Ramaswamy, who worked before as a sidestep fund analyst, is hedging his bets.
Axovant, for example, is seeking to find other uses for intepirdine, partial of which involves an ongoing Phase 2 test to provide a on-going brain commotion called Lewy physique dementia. (The marketplace is much smaller than for Alzheimer’s patients. The illness impacts 1.3 million Americans, compared with Alzheimer’s, which impacts 5.5 million.)
Another Roivant subsidiary, Enzyvant, is also seeking FDA capitulation to provide a singular pediatric illness called DiGeorge Syndrome and last month perceived a nomination from the FDA that should pierce it by the examination routine some-more quickly. (The capitulation trail is some-more streamlined in the case of singular diseases with life or death consequences.)
Roivant appears, too, to be focusing some-more nakedly on getting third-party biotech companies to partner with it on drug development. The idea, presumably, is that Roivant can bring them efficiencies by opening up its infrastructure to them.
Toward that end, Roivant progressing this week plugged $116 million into a company in which it already owned a stake: Arbutus, a hepatitis B-focused biotech firm. It’s a large play on the company. Then again, it’s chasing a big market. Approximately 350 million people in the universe are believed to have the disease. As partial of the deal, Arbutus will now rest on Roivant for functions that it would differently have had to build in-house.
Whether Roivant’s several moves will see a big adequate pay-off requires some-more time to learn. In the meantime, Roivant — which has now lifted some-more than $2 billion from investors, including from Founders Fund, and the sidestep supports Viking Global Investors and QVT Financial — must be anticipating its investors sojourn patient.
We reached out to Ramaswamy for this story; by a spokesman, he declined to comment.
Featured Image: panda3800/Shutterstock